Literature DB >> 26974875

Underlying mechanisms of cyclic peptide inhibitors interrupting the interaction of CK2α/CK2β: comparative molecular dynamics simulation studies.

Yue Zhou1, Na Zhang1, Wenjuan Chen1, Lijiao Zhao1, Rugang Zhong1.   

Abstract

Protein-protein interactions (PPIs) are fundamental to all biological processes. Recently, the CK2β-derived cyclic peptide Pc has been demonstrated to efficiently antagonize the CK2α/CK2β interaction and strongly affect the phosphorylation of CK2β-dependent CK2 substrate specificity. The binding affinity of Pc to CK2α is destroyed to different extents by two single-point mutations of Tyr188 to Ala (Y188A) and Phe190 to Ala (F190A), which exert negative effects on the inhibitory activity (IC50) of Pc against the CK2α/CK2β interaction from 3.0 μM to 54.0 μM and ≫100 μM, respectively. However, the structural influences of Y188A and F190A mutations on the CK2α-Pc complex remain unclear. In this study, comparative molecular dynamics (MD) simulations, principal component analysis (PCA), domain cross-correlation map (DCCM) analysis and energy calculations were performed on wild type (WT), Y188A mutant, and F190A mutant systems. The results revealed that ordered communications between hydrophobic and polar interactions were essential for CK2α-Pc binding in the WT system. In addition to the loss of the hydrogen bond between Gln36 of CK2α and Gly189 of Pc in the two mutants, the improper recognition mechanisms occurred through different pathways. These pathways included the weakened hydrophobic interactions in the Y188A mutant as well as decreased polar and hydrophobic interactions in the F190A mutant. The energy analysis results qualitatively elucidated the instability of the two mutants and energetic contributions of the key residues. This study not only revealed the structural mechanisms for the decreased binding affinity of Y188A and F190A mutant CK2α-Pc complexes, but also provided valuable clues for the rational design of CK2α/CK2β subunit interaction inhibitors with high affinity and specificity.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26974875     DOI: 10.1039/c5cp06276d

Source DB:  PubMed          Journal:  Phys Chem Chem Phys        ISSN: 1463-9076            Impact factor:   3.676


  6 in total

1.  Computational dissection of allosteric inhibition of the SH2 domain of Bcr-Abl kinase by the monobody inhibitor AS25.

Authors:  Mingfei Ji; Guodong Zheng; Xiaolong Li; Zhongqin Zhang; Guanqun Jv; Xiaowei Wang; Jialin Wang
Journal:  J Mol Model       Date:  2017-05-09       Impact factor: 1.810

2.  Identification of potential target endoribonuclease NSP15 inhibitors of SARS-COV-2 from natural products through high-throughput virtual screening and molecular dynamics simulation.

Authors:  Liang-Chang Hu; Chuan-Hua Ding; Hong-Ying Li; Zhen-Zhen Li; Ying Chen; Li-Peng Li; Wan-Zhong Li; Wen-Shan Liu
Journal:  J Food Biochem       Date:  2022-02-06       Impact factor: 2.720

3.  In Search of Small Molecule Inhibitors Targeting the Flexible CK2 Subunit Interface.

Authors:  Benoît Bestgen; Zakia Belaid-Choucair; Thierry Lomberget; Marc Le Borgne; Odile Filhol; Claude Cochet
Journal:  Pharmaceuticals (Basel)       Date:  2017-02-03

4.  Structural analysis of fungal pathogenicity-related casein kinase α subunit, Cka1, in the human fungal pathogen Cryptococcus neoformans.

Authors:  Belinda X Ong; Youngki Yoo; Myeong Gil Han; Jun Bae Park; Myung Kyung Choi; Yeseul Choi; Jeon-Soo Shin; Yong-Sun Bahn; Hyun-Soo Cho
Journal:  Sci Rep       Date:  2019-10-07       Impact factor: 4.379

5.  Discovery of holoenzyme-disrupting chemicals as substrate-selective CK2 inhibitors.

Authors:  Irina Kufareva; Benoit Bestgen; Paul Brear; Renaud Prudent; Béatrice Laudet; Virginie Moucadel; Mohamed Ettaoussi; Celine F Sautel; Isabelle Krimm; Matthias Engel; Odile Filhol; Marc Le Borgne; Thierry Lomberget; Claude Cochet; Ruben Abagyan
Journal:  Sci Rep       Date:  2019-11-04       Impact factor: 4.379

6.  Screening potential FDA-approved inhibitors of the SARS-CoV-2 major protease 3CLpro through high-throughput virtual screening and molecular dynamics simulation.

Authors:  Wen-Shan Liu; Han-Gao Li; Chuan-Hua Ding; Hai-Xia Zhang; Rui-Rui Wang; Jia-Qiu Li
Journal:  Aging (Albany NY)       Date:  2021-03-07       Impact factor: 5.682

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.